Thursday, August 3, 2017

BioLife Solutions - Chart of the Day

BioLife Solutions (BLFS) is the Barchart Chart of the Day.  The biomedical company has a Trend Spotter buy signal, a Weighted Alpha of 149.59+ and gained 114.81% in the last year.

The Chart of the Day belongs to BioLife Solutions (BLFS). I found the biomedical stock by using Barchart to sort today's Top Stocks to Own list first by the highest Weighted Alpha, then again by technical buy signals of 80% or more.  Since the Trend Spotter signaled a buy on 5/5 the stock gained 83.33%.

BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today.


The status of Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

  • 100% technical buy signals
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 6 new highs and up 48.40% in the last month
  • Relative Strength index 78.66%
  • Technical support level at 3.55
  • Recently traded at 3.86 with a 50 day moving average of 2.74
Fundamental factors:
  • Market Cap $48.38 million
  • Revenue expected to grow 5.40% this year and another 4.20% next year
  • Earnings estimated to increase 13.30% this year, and additional 6.20% next year and continue to compound at an annual rate of 10.00% for the next 5 years
  • Wall Street analysts issued 3 strong buy recommendations on the stock

No comments:

Post a Comment